yolk sac tumor
Conditions
Interventions
one:Oral thalidomide combined with TGA chemotherapy
Sponsors
Affiliated Cancer Hospital of Shandong First Medical University
Eligibility
Sex/Gender
All
Age
1 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. The child must have histological evidence of extracranial malignant germ cell tumor (yolk sac tumor); 2. When participating in the study, the age of the children must be less than 18 years old; 3. Children with yolk sac tumor who were drug resistant after at least two platinum-containing chemotherapy regiments or had relapsed within 3 months after chemotherapy, or had relapsed after sirolimus combined with TIC chemotherapy regiments; 4. The child must have a measurable lesion (as recorded by RECIST criteria) or an unevaluable disease with a tumor marker AFP greater than 5 times the upper limit of normal; 5. Lansky performance state score >= 50; 6. The child must have a life expectancy of more than six weeks; 7. The child must have recovered from all previous responses to anticancer therapy; 8. No serious organ dysfunction: normal cardiac function (cardiac ejection fraction > 50% or BNP < 2000 pg/ml); Liver function: the elevation of alanine aminotransferase was less than 5 times of the upper limit of normal value, and bilirubin was less than 3 times of the upper limit of normal value; Renal function: creatinine and urea nitrogen levels below the normal range; In blood routine, white blood cells were larger than 3 x10^9/L and platelets were larger than 100 x 10^9/L; 9. Obtain the guardian informed consent and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with other tumors; 2. Patients with heart, brain, liver, kidney and other organ failure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Medical images; | — |
Countries
China
Contacts
Public ContactYixiang Song
Affiliated Cancer Hospital of Shandong First Medical University
Outcome results
None listed